Busato, D.;                     Mossenta, M.;                     Dal Bo, M.;                     Macor, P.;                     Toffoli, G.    
        The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ductal Adenocarcinoma. Int. J. Mol. Sci. 2022, 23, 10279.
    https://doi.org/10.3390/ijms231810279
    AMA Style
    
                                Busato D,                                 Mossenta M,                                 Dal Bo M,                                 Macor P,                                 Toffoli G.        
                The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences. 2022; 23(18):10279.
        https://doi.org/10.3390/ijms231810279
    
    Chicago/Turabian Style
    
                                Busato, Davide,                                 Monica Mossenta,                                 Michele Dal Bo,                                 Paolo Macor,                                 and Giuseppe Toffoli.        
                2022. "The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ductal Adenocarcinoma" International Journal of Molecular Sciences 23, no. 18: 10279.
        https://doi.org/10.3390/ijms231810279
    
    APA Style
    
                                Busato, D.,                                 Mossenta, M.,                                 Dal Bo, M.,                                 Macor, P.,                                 & Toffoli, G.        
        
        (2022). The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences, 23(18), 10279.
        https://doi.org/10.3390/ijms231810279